Lawrence Green, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,239 of the $192,696 with a category attached, or 70.7%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2022 at $58,092 and has fallen 98.6% since, to $835 in 2025. Among neurology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 737 payments — averaging $261.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$45K
- Biogen$38K
- Genentech USA, Inc.$25K
- Teva Pharmaceuticals USA, Inc.$24K
- Lundbeck LLC$23K
- Bristol Myers Squibb$17K
- plus $21K from 32 others
What the payments were for
- Consulting fees$25,05713%
- Speaking & faculty fees$136,23971%
- Travel & lodging$18,85810%
- Food & beverage$12,3186%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 50 | $45,384 |
| Biogen | 104 | $38,376 |
| Genentech USA, Inc. | 75 | $24,553 |
| Teva Pharmaceuticals USA, Inc. | 37 | $24,307 |
| Lundbeck LLC | 63 | $22,789 |
| Bristol Myers Squibb | 78 | $16,767 |
| EMD Serono, Inc. | 68 | $8,908 |
| Sanofi | 30 | $6,597 |
| US Oncology Corporate, Inc. | 4 | $1,337 |
| AbbVie(2 entities) | 51 | $688 |
| Supernus Pharmaceuticals, Inc. | 82 | $556 |
| TG Therapeutics, Inc. | 10 | $293 |
| Novartis | 11 | $291 |
| Axsome Therapeutics, Inc. | 17 | $263 |
| Lilly USA, LLC | 6 | $181 |
| SK Life Science, Inc. | 2 | $179 |
| Kyowa Kirin, Inc. | 4 | $159 |
| UCB, Inc. | 4 | $142 |
| Eisai Inc. | 2 | $133 |
| Argenx US, Inc. | 1 | $97 |
| Acorda Therapeutics, Inc | 1 | $83 |
| Amgen | 4 | $70 |
| Sunovion Pharmaceuticals Inc. | 9 | $68 |
| C2n Diagnostics, LLC | 3 | $61 |
| Adamas Pharmaceuticals, Inc. | 3 | $60 |
| Genentech, Inc. | 3 | $50 |
| Revance Therapeutics, Inc. | 1 | $42 |
| Boston Scientific | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Sandoz | 1 | $33 |
| Aucta Pharmaceuticals, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Banner Life Sciences, LLC | 1 | $15 |
| Merck | 1 | $15 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$192,696 in reported general payments places this provider in the 95th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 14 | $129,247 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 12 | $121,332 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $110,658 |
| VumerityDiroximel Fumarate | 12 | $105,624 |
| Kesimpta PenOfatumumab | 11 | $88,814 |
| KeppraLevetiracetam | 44 | $64,350 |
| EpidiolexCannabidiol (Cbd) | 12 | $44,263 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $38,921 |
| LamictalLamotrigine | 26 | $36,173 |
| QuliptaAtogepant | 29 | $35,365 |
| Lacosamide | 195 | $30,010 |
| Emgality PenGalcanezumab-Gnlm | 33 | $29,363 |
| Nurtec OdtRimegepant Sulfate | 22 | $26,125 |
| TopamaxTopiramate | 27 | $24,249 |
| RytaryCarbidopa/Levodopa | 41 | $15,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $6,597 | $129,24714 claims |
| BiogenVumerity | $38,376 | $105,62412 claims |
| AbbVieQulipta | $688 | $35,36529 claims |
| Amneal Pharmaceuticals LLCRytary | $34 | $15,09141 claims |
| UCB, Inc.Neupro | $142 | $9,12011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 59 neurology providers in Idaho.
Other neurology in Nampa
- Mary RiverNampa$1K
- Michael DjernesNampa$101
- Bradford TalcottIdaho Falls$252K
- Stephen VincentIdaho Falls$156K
- Nina BozinovCoeur D Alene$76K
- Angela PanaCoeur D Alene$37K
- Erich GarlandIdaho Falls$33K
- Sergei KashirnyBoise$20K
- Richard HammondTwin Falls$16K
- Kylie AbeMeridian$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.